Chemotherapy-Induced Mucocutaneous Hyperpigmentation: A Case Series in Patients Receiving Etoposide-Based Regimens

Authors

  • Balodis L Department of Dermatology, University of Latvia, Riga, Latvia Author
  • Kovac I Department of Medical Oncology, University of Split, Split, Croatia Author
  • Balazova J Department of Oral Medicine, Comenius University, Bratislava, Slovakia Author

DOI:

https://doi.org/10.5281/zenodo.22644124

Keywords:

chemotherapy-induced hyperpigmentation, etoposide, melanonychia, mucocutaneous pigmentation, serpentine supravenous hyperpigmentation

Abstract

Background: Cytotoxic chemotherapy can produce a wide range of mucocutaneous and nail pigmentary changes that, although
generally benign, are frequently distressing to patients and can be mistaken for disease progression or an unrelated dermatologic
process. Etoposide-based regimens, commonly combined with bleomycin, platinum agents, or alkylating agents, represent a
recurrent clinical context in which such changes are observed. Objective: To synthesize the published literature on
chemotherapy-induced mucocutaneous and nail hyperpigmentation, with particular attention to reports arising in the setting of
etoposide-containing regimens, and to place these findings within the broader spectrum of cytotoxic-agent-associated pigmentary
toxicity. Methods: A narrative review was conducted of case reports, case series, and systematic reviews describing
chemotherapy-induced hyperpigmentation, focusing on mechanistic explanations, clinical patterns associated with etoposide and
its common regimen partners, agent-specific pigmentary syndromes across the wider cytotoxic drug class, and diagnostic and
management approaches. Findings: Etoposide is rarely isolated as a sole causative agent; most reports implicate concomitant
bleomycin, cyclophosphamide, or platinum compounds as the more likely proximate cause of the described pigmentation.
Well-characterized entities across the broader cytotoxic drug class include bleomycin-induced flagellate hyperpigmentation,
5-fluorouracil-associated serpentine supravenous streaking (reported in 2-5% of treated patients), and hydroxyurea-related
melanonychia after prolonged therapy. A large case series of 54 patients found cutaneous involvement in 83.3% and melanonychia
in 18.5%, while a pooled meta-analysis estimated antineoplastic-agent-associated hyperpigmentation at approximately 35.5% of
treated patients. Conclusions: Chemotherapy-induced mucocutaneous and nail hyperpigmentation is a common,
pattern-recognizable, and generally self-limited toxicity best managed conservatively, with dermatologic referral reserved for
diagnostic uncertainty or marked cosmetic distress; further case-level reporting specific to etoposide, distinct from its regimen
partners, remains warranted.

References

Tisack A, Mohammad TF (2024) Drug-Induced Pigmentation: A Review. Drugs, 84(9):1071-1091, DOI:10.1007/s40265-024-02062-z.

Alharithy R, Alotaibi K, Bin Salamah R, Altamimi R, Alqntash N, Alsarhan R, Khosyfan L, Alrowais S (2026) Drug induced hyperpigmentation: systematic review and meta-analysis. Frontiers in Medicine, 13:1674278, DOI:10.3389/fmed.2026.1674278.

Mutafoğlu Uysal K, Sarıalioğlu F, Olgun N (2001) Bleomycin-induced hyperpigmentation and hypersensitivity reactions to etoposide and vinblastine in a child with endodermal sinus tumor. The Turkish Journal of Pediatrics, 43(2):172-174, DOI:10.24953/turkjpediatr.2001.3046.

Hanafi T, Titou H, Kerrouch H, Frikh R, Hjira N, Boui M (2020) Hyperpigmentation Associated with Anti-Tumor Chemotherapy: A Series of 54 Cases, Demo-Topographic Aspects and Interest of the Dermatological Intervention. International Journal of Cancer and Clinical Research, 7(1):130, DOI:10.23937/2378-3419/1410130.

Giménez García RM, Carrasco Molina S (2019) Drug-Induced Hyperpigmentation: Review and Case Series. Journal of the American Board of Family Medicine, 32(4):628-638, DOI:10.3122/jabfm.2019.04.180212.

Gropper CA, Don PC, Sadjadi MM (1993) Nail and skin hyperpigmentation associated with hydroxyurea therapy for polycythemia vera. International Journal of Dermatology, 32(10):731-733, DOI:10.1111/j.1365-4362.1993.tb02745.x.

Koley S, Choudhary S, Salodkar A (2010) Melanonychia and skin hyperpigmentation with hydroxyurea therapy. Indian Journal of Pharmacology, 42(1):60-61, DOI:10.4103/0253-7613.62394.

Karanth SS, Gupta A, Prabhu MM (2014) Melanonychia and mucocutaneous hyperpigmentation from hydroxyurea use for the treatment of essential thrombocytosis. Singapore Medical Journal, 55(1):e5-e7, DOI:10.11622/smedj.2013187.

Letete N, Vaz D (2024) Late-Onset Hydroxyurea-Induced Melanonychia and Tongue Hyperpigmentation in a Patient With Polycythemia Vera: A Case Report. Cureus, 16(2):e53642, DOI:10.7759/cureus.53642.

Kim KJ, Chang SE, Choi JH, Sung KJ, Moon KC, Koh JK (2002) Periungual hyperpigmentation induced by cisplatin. Clinical and Experimental Dermatology, 27(2):118-119, DOI:10.1046/j.1365-2230.2002.00972.x.

Shan J, Obiakor BC, Cheng J, Francois RA, Dobry AS (2024) Serpentine supravenous hyperpigmentation induced by chemotherapy: a systematic review. Archives of Dermatological Research, 316(6):215, DOI:10.1007/s00403-024-03057-2.

Larson KN, Gagnon AL, Wilson BB (2017) Bleomycin-induced flagellate hyperpigmentation. Clinical Case Reports, 5(4):429-430, DOI:10.1002/ccr3.831.

Chen X, Zheng C, Wang K, Zhai L (2025) Bleomycin-induced flagellate-like skin pigmentation in a 15-year-old girl: a case report and review. Frontiers in Medicine, 12:1610203, DOI:10.3389/fmed.2025.1610203.

Dave S, Thappa DM (2003) Peculiar pattern of nail pigmentation following cyclophosphamide therapy. Dermatology Online Journal, 9(3):8, DOI:10.5070/D36Q63G6NR.

Kumar S, Dixit R, Karmakar S, Paul S (2010) Unusual nail pigmentation following cyclophosphamide-containing chemotherapy regimen. Indian Journal of Pharmacology, 42(4):243-244, DOI:10.4103/0253-7613.68433.

Pangti R, Gupta S (2022) Blue Lunula Due to a Combination Chemotherapy Not Reported Before. Indian Dermatology Online Journal, 13(4):546-547, DOI:10.4103/idoj.idoj_927_20.

Yule SM, Pearson ADJ, Craft AW, Teresi ME, Murry DJ (1994) Ifosfamide-induced hyperpigmentation. Cancer, 73(1):240, D OI:10.1002/1097-0142(19940101)73:1<240::AID-CNCR2820730 141>3.0.CO;2-6.

Reyes-Habito CM, Roh EK (2014) Cutaneous reactions to chemotherapeutic drugs and targeted therapies for cancer: part I. Journal of the American Academy of Dermatology, 71(2):203.e1-203.e12, DOI:10.1016/j.jaad.2014.04.014.

Reyes-Habito CM, Roh EK (2014) Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: part II. Journal of the American Academy of Dermatology, 71(2):217.e1-217.e11, DOI:10.1016/j.jaad.2014.04.013.

Cohen PR (2016) Paclitaxel-associated reticulate hyperpigmentation: report and review of chemotherapy-induced reticulate hyperpigmentation. World Journal of Clinical Cases, 4(12):390-400, DOI:10.12998/wjcc.v4.i12.390.

Sutaria A, Saini K, Shah B, Brahmbhatt V, Parmar K (2019) Cutaneous adverse drug reactions to targeted chemotherapeutic drugs: A clinico-epidemiological study. Indian Journal of Dermatology, 64(6):471-478, DOI:10.4103/ijd.IJD_491_18.

Deutsch A, Leboeuf NR, Lacouture ME, McLellan BN (2020) Dermatologic Adverse Events of Systemic Anticancer Therapies: Cytotoxic Chemotherapy, Targeted Therapy, and Immunotherapy. American Society of Clinical Oncology Educational Book, 40:485-500, DOI:10.1200/EDBK_289911.

Downloads

Published

2023-12-30